Background
Cristina Adriana Popa
A dose of CONFIDENCE: Building evidence for ...

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Background
swapnil hiremath
From single shots to strategy: How CAPTIVATE is ...

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Background
Cristina Adriana Popa
Are E-Nudges Enough to Push Guideline-Based CKD ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

Are E-Nudges Enough to Push Guideline-Based CKD Therapy?
Background
Brian Rifkin
STAMP of Approval: Tacrolimus vs MMF in ...

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance

Background

Longer is Better, Except when it is Not, Really: Hemodialysis Edition

Longer is Better, Except when it is Not, Really: Hemodialysis Edition

The ACTIVE trial tested the hypothesis that longer dialysis would be better for quality of life. Sadly, this did not turn out to be the case. Is the end of longer being better? Join us as we dissect the study at the next NephJC.

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING? 

Encapsulating Peritoneal Sclerosis: The ISPD Advice

Encapsulating Peritoneal Sclerosis: The ISPD Advice

This week, we will discuss the fresh-off-the-press ISPD guidelines on encapsulating peritoneal sclerosis. We are happy to have support from the ISPD for organizing this - and making the manuscript open, and also the ISPD Vancouver 2018 team, who will be co-hosting the #NephJC chat. 

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.